Pruritus is a major symptom of skin disease. The quest to identify a valid and reliable method to assess this important symptom has led to the development of a myriad of measurement tools. Some clinical trials using subjective measurements of itch intensity have reported itch intensity levels in psoriasis that are close to severity levels found in atopic dermatitis. Although it is possible that we have previously underestimated the severity of pruritus in psoriasis, these unexpected findings prompted us to review and evaluate these subjective methodologies. We provide an overview of the current tools available to measure itch severity, including subjective rating scales and questionnaires and objective measures of scratch activity through videotape observation and wrist actigraphy. We discuss the advantages and limitations of these methods and encourage consideration of a novel objective method of evaluation.
Get full access to this article
View all access options for this article.
References
1.
SavinJA. How should we define itching?. J Am Acad Dermatol, 1998; 39(2 Pt 1): 268–269.
2.
WahlgrenCF. Measurement of itch. Semin Dermatol, 1995; 14(4): 277–284.
3.
StanderS, AugustinM, ReichA, et al.Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. Acta Derm Venereol, 2013; 93(5): 509–514.
4.
BenjaminK, WaterstonK, RussellM, et al.The development of an objective method for measuring scratch in children with atopic dermatitis suitable for clinical use. J Am Acad Dermatol, 2004; 50(1): 33–40.
5.
BringhurstC, WaterstonK, SchofieldO, et al.Measurement of itch using actigraphy in pediatric and adult populations. J Am Acad Dermatol, 2004; 51(6): 893–898.
6.
BenderBG, BallardR, CanonoB, et al.Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol, 2008; 58(3): 415–420.
7.
MurrayCS, ReesJL. Are subjective accounts of itch to be relied on? The lack of relation between visual analogue itch scores and actigraphic measures of scratch. Acta Derm Venereol, 2011; 91(1): 18–23.
8.
BergasaNV, TalbotTL, AllingDW, et al.A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology, 1992; 102(2): 544–549.
9.
HonKL, LamMC, LeungTF, et al.Nocturnal wrist movements are correlated with objective clinical scores and plasma chemokine levels in children with atopic dermatitis. Br J Dermatol, 2006; 154(4): 629–635.
10.
BushnellDM, MartinML, McCarrierK, et al.Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatol Treat, 2013; 24(5): 356–360.
11.
KunzB, OranjeAP, LabrezeL, et al.Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology, 1997; 195(1): 10–19.
12.
GuptaMA, GuptaAK, KirkbyS, et al.Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol, 1988; 124(7): 1052–1057.
13.
KruegerG, KooJ, LebwohlM, et al.The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol, 2001; 137(3): 280–284.
14.
Chrostowska-PlakD, SalomonJ, ReichA, et al.Clinical aspects of itch in adult atopic dermatitis patients. Acta Derm Venereol, 2009; 89(4): 379–383.
15.
YosipovitchG, GoonAT, WeeJ, et al.Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol, 2002; 41(4): 212–216.
16.
FortuneDG, RichardsHL, MainCJ, et al.What patients with psoriasis believe about their condition. J Am Acad Dermatol, 1998; 39(2 Pt 1): 196–201.
17.
YosipovitchG, GoonA, WeeJ, et al.The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol, 2000; 143(5): 969–973.
18.
SzepietowskiJC, ReichA, WisnickaB. Itching in patients suffering from psoriasis. Acta Dermatovenerol Croatica, 2002; 10(4): 221–226.
19.
Regeneron Pharmaceuticals Inc. Sanofi and Regeneron report positive proof-of-concept data for dupilumab, an IL-4R alpha antibody, in atopic dermatitis. 2013. Available at: http://investor.regeneron.com/releasedetail.cfm?releaseid=744703. Accessed December12, 2013.
MrowietzU, KragballeK, ReichK, et al.An assessment of adalimumab efficacy in three phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Br J Dermatol, 2013; 168(2): 374–380.
22.
O’NeillJL, ChanYH, RappSR, et al.Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a Web-based questionnaire. Acta Derm Venereol, 2011; 91(5): 537–540.
23.
PhanNQ, BlomeC, FritzF, et al.Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol, 2012; 92(5): 502–507.
24.
PapoiuAD, Valdes-RodriguezR, NattkemperLA, et al.A novel topical formulation containing strontium chloride significantly reduces the intensity and duration of cowhage-induced itch. Acta Derm Venereol, 2013; 93(5): 520–526.
25.
TheunisJ, BlackD, DegouyA, et al.Comparison of perceived itch induced by skin prick-tests with histamine and codeine. Acta Derm Venereol, 2008; 88(5): 455–457.
26.
MagerlW, WestermanRA, MohnerB, et al.Properties of transdermal histamine iontophoresis: differential effects of season, gender, and body region. J Invest Dermatol, 1990; 94(3): 347–352.
27.
WahlgrenCF, EkblomA, HagermarkO. Some aspects of the experimental induction and measurement of itch. Acta Derm Venereol, 1989; 69(3): 185–189.
28.
ReichA, HeisigM, PhanNQ, et al.Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol, 2012; 92(5): 497–501.
29.
SvenssonE. Concordance between ratings using different scales for the same variable. Stat Med, 2000; 19(24): 3483–3496.
30.
DixonJS, BirdHA. Reproducibility along a 10 cm vertical visual analogue scale. Ann Rheum Dis, 1981; 40(1): 87–89.
31.
FurueM, EbataT, IkomaA, et al.Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. Acta Derm Venereol, 2013; 93(2): 214–215.
32.
ScottJ, HuskissonEC. Graphic representation of pain. Pain, 1976; 2(2): 175–184.
33.
RevillSI, RobinsonJO, RosenM, et al.The reliability of a linear analogue for evaluating pain. Anaesthesia, 1976; 31(9): 1191–1198.
34.
Stahle-BackdahlM, WahlgrenCF, HagermarkO. Computerized recording of itch in patients on maintenance hemodialysis. Acta Derm Venereol, 1989; 69(5): 410–414.
35.
WahlgrenCF, HagermarkO, BergstromR. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol, 1990; 122(4): 545–551.
36.
WahlgrenCF, HagermarkO, BergstromR, et al.Evaluation of a new method of assessing pruritus and antipruritic drugs. Skin Pharmacol, 1988; 1(1): 3–13.
37.
WahlgrenCF, ScheyniusA, HagermarkO. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol, 1990; 70(4): 323–329.
38.
A Trio of Solutions. Murrysville, PA: Philips Respironics; 2012.
39.
KruegerGG, LangleyRG, FinlayAY, et al.Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol, 2005; 153(6): 1192–1199.
40.
FeldmanSR, KimballAB, KruegerGG, et al.Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol, 2005; 53(5): 887–889.
41.
GelfandJM, KimballAB, MostowEN, et al.Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health, 2008; 11(3): 400–407.
42.
GottliebA, FengJ, HarrisonDJ, et al.Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis. J Am Acad Dermatol, 2010; 63(4): 580–586.
43.
StanderS, BlomeC, BreilB, et al.Assessment of pruritus—current standards and implications for clinical practice: consensus paper of the Action Group Pruritus Parameter of the International Working Group on Pruritus Research (AGP). Hautarzt, 2012; 63(7): 521–522, 524–531.
44.
Chrostowska-PlakD, ReichA, SzepietowskiJC. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol, 2013; 27(2): e239–e242.
45.
WeisshaarE, DalgardF. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol, 2009; 89(4): 339–350.
46.
HousmanTS, PatelMJ, CamachoF, et al.Use of the Self-administered Eczema Area and Severity Index by parent caregivers: results of a validation study. Br J Dermatol, 2002; 147(6): 1192–1198.
47.
Vourc’h-JourdainM, BarbarotS, TaiebA, et al.Patient-oriented SCORAD: a self-assessment score in atopic dermatitis. A preliminary feasibility study. Dermatology, 2009; 218(3): 246–251.
48.
HonKL, LeungTF, WongY, et al.Lesson from performing SCORADs in children with atopic dermatitis: subjective symptoms do not correlate well with disease extent or intensity. Int J Dermatol, 2006; 45(6): 728–730.
49.
OranjeAP. Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol, 2011; 41: 149–155.
50.
Lob-CorziliusT, BöerS, ScheeweS, et al.The ‘Skin Detective Questionnaire’: a survey tool for self-assessment of patients with atopic dermatitis. First results of its application. Dermatol Psychosom, 2004; 5: 141–146.
51.
GottliebAB, ChaudhariU, BakerDG, et al.The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician’s Global Assessment (PGA): a comparison. J Drugs Dermatol, 2003; 2(3): 260–266.
52.
FleischerAB Jr, FeldmanSR, RappSR, et al.Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol, 1996; 107(1): 26–29.
53.
ReichA, HrehorowE, SzepietowskiJC. Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol, 2010; 90(3): 257–263.
54.
ZachariaeR, ZachariaeCO, LeiU, et al.Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients. Acta Derm Venereol, 2008; 88(2): 121–127.
55.
PrignanoF, RicceriF, PescitelliL, et al.Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clin Cosmet Investig Dermatol, 2009; 2: 9–13.
56.
RoblinD, WickramasingheR, YosipovitchG. Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity. J Am Acad Dermatol, 2014; 70(2): 390–391.
57.
CharmanCR, VennAJ, WilliamsHC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol, 2004; 140(12): 1513–1519.
58.
JanowskiK, SteudenS, BogaczewiczJ. Clinical and psychological characteristics of patients with psoriasis reporting various frequencies of pruritus. Int J Dermatol, 2014; 53(7): 820–829.
59.
AmatyaB, WennerstenG, NordlindK. Patients’ perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol, 2008; 22(7): 822–826.
60.
ChernyshovPV.Health related quality of life in adult atopic dermatitis and psoriatic patients matched by disease severity. G Ital Dermatol Venereol, 2014.
61.
AugustinM, RadtkeMA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res, 2014; 14(4): 559–568.
KruegerGG, PappKA, StoughDB, et al.A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol, 2002; 47(6): 821–833.
64.
LeonardiCL, PowersJL, MathesonRT, et al.Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 2003; 349(21): 2014–2022.
65.
PappK, BissonnetteR, KruegerJG, et al.The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol, 2001; 45(5): 665–674.
66.
EversAW, LuY, DullerP, et al.Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol, 2005; 152(6): 1275–1281.
67.
WeisshaarE, GielerU, KupferJ, et al.Questionnaires to assess chronic itch: a consensus paper of the special interest group of the International Forum on the Study of Itch. Acta Derm Venereol, 2012; 92(5): 493–496.
68.
DesaiNS, PoindexterGB, MonthropeYM, et al.A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol, 2008; 59(2): 234–244.
69.
YosipovitchG, ZuckerI, BonerG, et al.A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol, 2001; 81(2): 108–111.
70.
MajeskiCJ, JohnsonJA, DavisonSN, et al.Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. Br J Dermatol, 2007; 156(4): 667–673.
DarsowU, SchareinE, SimonD, et al.New aspects of itch pathophysiology: component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire’. Int Arch Allergy Immunol, 2001; 124(1–3): 326–331.
73.
SzepietowskiJ. Selected elements of the pathogenesis of pruritus in hemodialysis patients: my own study. Dermatology and Venereology, University School of Medicine, Wroclaw, Poland. Med Sci Monit, 1996; 2: 343–347.
74.
QarqazFAA, AboosiMA, Al-ShiyabD, et al.Using pruritus grading system for measurement of pruritus in patients with diseases associated with itch. J Med J, 2012; 46(1): 39–44.
75.
BlomeC, AugustinM, SiepmannD, et al.Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol, 2009; 161(5): 1143–1148.
76.
ElmanS, HynanLS, GabrielV, et al.The 5-D itch scale: a new measure of pruritus. Br J Dermatol, 2010; 162(3): 587–593.
77.
SampognaF, GisondiP, MelchiCF, et al.Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol, 2004; 151(3): 594–599.
78.
DawnA, PapoiuAD, ChanYH, et al.Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol, 2009; 160(3): 642–644.
79.
SchmittJ, LanganS, DeckertS, et al.Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol, 2013; 132(6): 1337–1347.
80.
ChamlinSL, KaoJ, FriedenIJ, et al.Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol, 2002; 47(2): 198–208.
81.
AtakanN, ErdemC. The efficacy, tolerability and safety of a new oral formulation of Sandimmun—Sandimmun Neoral in severe refractory atopic dermatitis. J Eur Acad Dermatol Venereol, 1998; 11(3): 240–246.
82.
RulloVE, SegatoA, KirshA, et al.Severity scoring of atopic dermatitis: a comparison of two scoring systems. Allergol Immunopathol (Madr.), 2008; 36(4): 205–211.
83.
WolkerstorferA, de Waard van der SpekFB, GlazenburgEJ, et al.Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol, 1999; 79(5): 356–359.
84.
Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology, 1993; 186(1): 23–31.
85.
OranjeAP, StalderJF, TaiebA, et al.Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr Allergy Immunol, 1997; 8(1): 28–34.
86.
SchaferT, DockeryD, KramerU, et al.Experiences with the severity scoring of atopic dermatitis in a population of German pre-school children. Br J Dermatol, 1997; 137(4): 558–562.
87.
SprikkelmanAB, TupkerRA, BurgerhofH, et al.Severity scoring of atopic dermatitis: a comparison of three scoring systems. Allergy, 1997; 52(9): 944–949.
88.
CharmanCR, VennAJ, WilliamsHC. Reliability testing of the Six Area, Six Sign Atopic Dermatitis severity score. Br J Dermatol, 2002; 146(6): 1057–1060.
89.
EbataT, AizawaH, KamideR, et al.The characteristics of nocturnal scratching in adults with atopic dermatitis. Br J Dermatol, 1999; 141(1): 82–86.
90.
EbataT, IwasakiS, KamideR, et al.Use of a wrist activity monitor for the measurement of nocturnal scratching in patients with atopic dermatitis. Br J Dermatol, 2001; 144(2): 305–309.
91.
BijakM, MayrW, RafoltD, et al.Pruritometer 2: portable recording system for the quantification of scratching as objective criterion for the pruritus. Biomed Tech (Berl), 2001; 46(5): 137–141.
92.
HonKL, ChiuLS, LamMC, et al.Measurement of pruritus in a Chinese woman with pemphigoid gestationis using a wrist movement detector. Int J Dermatol, 2008; 47(1): 64–67.
93.
HonKL, LamMC, LeungTF, et al.Assessing itch in children with atopic dermatitis treated with tacrolimus: objective versus subjective assessment. Adv Ther, 2007; 24(1): 23–28.
94.
PetersenJ, AustinD, SackR, et al.Actigraphy-based scratch detection using logistic regression. IEEE J Biomed Health Inform, 2013; 17(2): 277–283.
95.
WoottonCI, KollerK, LawtonS, et al.Are accelerometers a useful tool for measuring disease activity in children with eczema? Validity, responsiveness to change, and acceptability of use in a clinical trial setting. Br J Dermatol, 2012; 167(5): 1131–1137.
96.
FeuersteinJ, AustinD, SackR, et al.Wrist actigraphy for scratch detection in the presence of confounding activities. Conf Proc IEEE Eng Med Biol Soc, 2011; 2011: 3652–3655.
97.
NoroY, OmotoY, UmedaK, et al.Novel acoustic evaluation system for scratching behavior in itching dermatitis: rapid and accurate analysis for nocturnal scratching of atopic dermatitis patients. J Dermatol, 2014; 41(3): 233–238.
98.
FDA Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed April20, 2014.
99.
EbataT, AizawaH, KamideR. An infrared video camera system to observe nocturnal scratching in atopic dermatitis patients. J Dermatol, 1996; 23(3): 153–155.
